Home Mereo Biopharma

Mereo Biopharma

Mereo Biopharma

Mereo Biopharma
Category
Business Description
Mereo BioPharma is a UK-based international biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for people in both oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT) has completed a Phase 1a dose-escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.
Based in
London
Tags
Biopharma, Biotechnology, Health Care, Innovation Management
Total Funding
Above €25 million
Founded
2015
Website
http://mereobiopharma.com/
💡 You're a corporate or investor and looking for startups that are innovating in the same market as Mereo Biopharma? We're happy to assist you with our Startup Sourcing service.